You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
The agreement aims to improve patient access to coagulation disorders treatments in Europe
The goal is to provide wider access to plasma-derived therapies for coagulation disorders the world over
International medical journal hosts review of contract plasma fractionation dynamics
It is the active component of the medicinal product, the one responsible for its healing effect.
The molecules of a drug passing from the site of delivery into the bloodstream.